Every article, presentation, spotlight, and news item we've tagged to Hallmarks of Aging.
Showing 217–239 of 239
ARPA-H has awarded $22 million to Linnaeus Therapeutics to test LNS8801, an oral drug designed to preserve physical and cognitive function in aging before decline occurs. The approach represents a shift from treating age-related disease toward maintaining the integrated capacities that sustain independence and resilience.
Temozolomide-induced senescent glioblastoma cells exhibit dynamic morphological states with distinct survival mechanisms and drug sensitivities. This heterogeneity and plasticity have direct implications for how chemotherapy resistance develops and why combination senotherapeutic strategies may be necessary to prevent tumor recurrence.
SuperAgers—individuals over 80 with memory performance matching those decades younger—maintain roughly twice the neurogenic capacity of age-matched peers, driven by preserved epigenetic regulation that keeps regenerative neural programs accessible. This finding reframes cognitive aging from inevitable decline to a regulated, potentially modifiable biological process.
Research on killifish demonstrates that aging occurs in discrete stages rather than linear decline, with movement patterns in mid-life serving as a measurable predictor of remaining lifespan. This staged aging model suggests that locomotor capacity reflects underlying systemic vulnerability across multiple organ systems.
Stanford researchers created the first comprehensive atlas of lysosomal proteins across four major brain cell types, revealing cell-specific patterns that explain how waste accumulation contributes to Alzheimer's, Parkinson's, and other neurodegenerative diseases. This cellular-level mapping shifts neurodegeneration research toward early prevention rather than late-stage intervention, with direct implications for maintaining cognitive function across the lifespan.
Adequate hydration is a critical but often overlooked factor in healthy aging. Dehydration impairs multiple physiological systems and accelerates age-related decline, making hydration status a measurable and modifiable component of longevity strategy.
Researchers have mapped 250 genes essential for human muscle fiber formation using a CRISPR screening platform, identifying previously unknown genetic drivers of muscle development and linking 41 of these genes to developmental muscle defects. This foundational knowledge directly informs understanding of sarcopenia and age-related muscle loss, where the same fusion mechanisms that fail in rare genetic disorders deteriorate progressively with age.
João Pedro de Magalhães and Zhuang Zhuang Han have published a peer-reviewed ethical framework addressing persistent public and scientific concerns about longevity science. The paper provides researchers with evidence-informed arguments to address misconceptions about aging intervention—concerns that have remained largely consistent over two decades despite scientific progress.
Lipid mediators in platelet transfusions—particularly lysophosphatidic acid, lysophosphatidylcholine, and sphingosine-1-phosphate—decline with donor age and correlate with adverse transfusion reactions through altered platelet and endothelial cell activation. This finding suggests that donor age-related changes in lipid signaling directly influence transfusion safety and vascular biology.
Severe infections carry independent dementia risk beyond what frailty and comorbidities explain, suggesting infection-related mechanisms directly contribute to cognitive decline. This identifies a modifiable pathway distinct from typical aging trajectories.
FGF21 activates a cellular repair pathway in spinal disc cells by upregulating SIRT1, which deacetylates FOXO3 and triggers mitochondrial autophagy, thereby suppressing cell senescence and slowing intervertebral disc degeneration. This identifies a targetable molecular axis with direct relevance to preventing age-related spinal structural decline and associated disability.
Celularity licensed its placental-derived biomaterials portfolio for up to $35 million in non-dilutive capital, allowing the company to redirect resources toward cell therapies targeting senescence, inflammation, and tissue degeneration. This repositioning reflects a strategic shift from broad biomaterials commercialization to targeted longevity interventions.
Mitrix Bio has reported preliminary Phase 1 safety data from mitochondrial transplantation in two older adults with no observed adverse effects, while simultaneously launching clinics offering the intervention under Right to Try frameworks. This represents a transition from preclinical work to early clinical deployment, though data density remains limited relative to narrative momentum.
Severe infections show a persistent association with dementia risk that remains significant even after adjusting for frailty and age-related conditions, suggesting the connection operates through mechanisms independent of pre-existing disease burden. This finding extends prior research and points toward infection-related pathways that directly influence cognitive decline.
A longitudinal study of over 11,000 adults aged 65 and older found that 45% showed improvement in cognitive and/or physical functioning over 12 years, with positive age-related beliefs predicting these gains. This challenges the pervasive assumption that chronological aging inevitably produces decline and demonstrates that improvement remains physiologically possible in later life.
Interferon-gamma (IFN-γ), a common immune signaling molecule, emerges as a blood-based biomarker capable of distinguishing Alzheimer's disease from healthy aging with high accuracy, particularly in individuals carrying the APOE ε4 genetic variant. The finding suggests a scalable pathway for early detection and monitoring, shifting the disease profile toward immune-driven pathology.
Spaceflight stressors including microgravity and radiation accelerate biological aging pathways in astronauts, providing a compressed model for studying age-related disease mechanisms. This natural experiment offers direct evidence of how extreme environmental conditions trigger aging processes that occur more gradually in terrestrial populations.
Lithuania is organizing a national assembly in 2026 that positions healthy aging as a matter of state policy rather than specialist medicine, connecting geroscience, prevention, and parliamentary governance across the country. The initiative reflects demographic urgency—projected 20% population decline by 2050 and low healthy life expectancy relative to overall lifespan—and signals a structural shift in how governments approach longevity as infrastructure rather than aspiration.
Older adults who developed cancer over three years showed accelerated decline in physical function and biological aging markers compared to cancer-free peers, even when starting from similar baseline health. Physical deterioration preceded or accompanied cancer diagnosis, suggesting measurable functional decline tracks with malignant disease progression.
RORA, a transcription factor, exacerbates age-related cataract by targeting the prion protein (PRNP) and triggering oxidative stress-induced senescence and apoptosis in lens epithelial cells. Inhibiting RORA or blocking the RORA-PRNP axis restores cellular resilience and may offer a therapeutic target for cataract prevention and reversal.
Nanoplastics have been detected in human brain tissue and show correlation with neurodegenerative disease severity and accelerated aging markers. The particles' ability to cross biological barriers and interact with pathological proteins suggests chronic, low-level exposure represents a longevity risk distinct from acute toxicity.
Older adults exhibit measurable declines in everyday decision-making driven by sensory and cognitive changes, with environmental design and support structures demonstrating capacity to mitigate these effects. This directly impacts functional independence and quality of life across the lifespan.
A 75-year-old carrier of a dominant Alzheimer's mutation remained cognitively intact, suggesting that genetic predisposition does not determine disease expression. This case indicates that protective mechanisms—possibly involving heat shock proteins and cellular stress response—can override genetic risk, with implications for understanding preventive intervention strategies in neurodegeneration.
